Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Sarepta Therapeutics (AB3A) Stock Price & Analysis

0 Followers

AB3A Stock Chart & Stats

No data to display
Day’s Range
N/A
52-Week Range
N/A
Previous Close
N/A
Volume
N/A
Average Volume (3M)
N/A
Market Cap
CHF 1.47B
Enterprise Value
CHF 2.10B
Total Cash (Recent Filing)
CHF 878.78M
Total Debt (Recent Filing)
CHF 1.05B
Price to Earnings (P/E)
185.3
Beta
1.20
Next Earnings
Mar 03, 2027 (Est.)
EPS Estimate
-0.29
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Long-term Revenue Scale

Sarepta has materially expanded its commercial revenue base over several years, demonstrating meaningful product adoption and a larger operating platform. This scale can support continued investment in genetic-medicine programs and improve the company’s ability to absorb development costs over the next several quarters.

Established DMD Franchise

The exon-skipping franchise provides an established commercial foundation supported by patient adherence, new enrollments, and a large treated population. That recurring base can help sustain demand while Sarepta develops additional indications and works to stabilize the newer ELEVIDYS business.

Improved Liquidity And Cash Generation

Nearly $1 billion of cash and investments, together with reported year-to-date cash generation, gives Sarepta flexibility to fund clinical programs and absorb operating variability. Stronger liquidity also reduces immediate reliance on external capital while management advances multiple pipeline catalysts.

Bears Say

ELEVIDYS-driven Revenue Decline

Recent revenue contraction indicates that ELEVIDYS has not yet provided dependable growth after its launch contribution. Continued weakness could reduce operating leverage, constrain investment capacity, and leave overall performance more dependent on the mature PMO franchise during the next two to six months.

Margin And Earnings Volatility

Take-or-pay charges and uneven product mix are weighing on gross margin, while the quarterly GAAP operating loss highlights unstable earnings quality. Even with non-GAAP profitability, recurring cost variability can make cash conversion and reported profitability difficult to sustain consistently.

Emerging Exon-skipping Competition

A potential competing exon 51 therapy creates a structural threat to Sarepta’s established franchise, particularly as new patients and prescribers evaluate alternatives. Management does not expect immediate wholesale switching, but competitive pressure could increase over time and limit future growth.

Sarepta Therapeutics News

AB3A FAQ

What is Sarepta Therapeutics’s market cap?
Sarepta Therapeutics’s market cap is CHF1.47B.
When is Sarepta Therapeutics’s upcoming earnings report date?
Sarepta Therapeutics’s next earnings report is estimated for Mar 03, 2027 (not yet confirmed), which is in 111 days.
How were Sarepta Therapeutics’s earnings last quarter?
Sarepta Therapeutics released its earnings results on Nov 05, 2026. The company reported -CHF0.223 earnings per share for the quarter, missing the consensus estimate of CHF0.065 by -CHF0.288.
Is Sarepta Therapeutics overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Sarepta Therapeutics pay dividends?
Sarepta Therapeutics does not currently pay dividends.
What is Sarepta Therapeutics’s EPS estimate?
Sarepta Therapeutics’s EPS estimate is -0.29.
How many shares outstanding does Sarepta Therapeutics have?
Sarepta Therapeutics has 107,235,850 shares outstanding.
What happened to Sarepta Therapeutics’s price movement after its last earnings report?
Sarepta Therapeutics reported an EPS of -CHF0.223 in its last earnings report, missing expectations of CHF0.065. Following the earnings report the stock price went same ―.
Which hedge fund is a major shareholder of Sarepta Therapeutics?
Hedge funds hold Sarepta Therapeutics shares: the largest hedge-fund position in Sarepta Therapeutics is 454,886,119 shares, and hedge funds decreased their holdings by 4.0M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology